Parallax Volatility Advisers’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.45M Sell
138,300
-64,600
-32% -$3.06M 0.01% 557
2025
Q4
$10.3M Buy
202,900
+100,300
+98% +$5.13M 0.02% 448
2025
Q3
$5.69M Buy
102,600
+36,100
+54% +$2.11M 0.01% 641
2025
Q2
$4.59M Buy
66,500
+55,800
+521% +$3.8M 0.01% 644
2025
Q1
$743K Buy
10,700
+7,200
+206% +$595K ﹤0.01% 1116
2024
Q4
$301K Sell
3,500
-30,500
-90% -$3.3M ﹤0.01% 1603
2024
Q3
$4.05M Buy
34,000
+33,900
+33,900% +$4.52M 0.01% 875
2024
Q2
$14.3K Sell
100
-49,700
-100% -$6.59M ﹤0.01% 1850
2024
Q1
$6.39M Buy
+49,800
New +$5.93M 0.01% 643
2022
Q4
Sell
-114,000
Closed -$5.68M 3141
2022
Q3
$5.68M Buy
+114,000
New +$6.11M 0.01% 966
2022
Q2
Sell
-143,600
Closed -$7.97M 3149
2022
Q1
$7.97M Buy
+143,600
New +$7.37M ﹤0.01% 829
2020
Q3
Sell
-135,600
Closed -$4.44M 3122
2020
Q2
$4.44M Buy
+135,600
New +$4.33M 0.01% 1119
2018
Q1
Sell
-59,800
Closed -$1.6M 3600
2017
Q4
$1.6M Sell
59,800
-1,800
-3% -$45.8K ﹤0.01% 1002
2017
Q3
$1.48M Buy
+61,600
New +$1.39M ﹤0.01% 937
2016
Q3
Sell
-25,000
Closed -$672K 3579
2016
Q2
$672K Buy
+25,000
New +$686K ﹤0.01% 1343

Other funds holding NVO

Parallax Volatility Advisers's NVO Position: Q1 2026 in Review

Parallax Volatility Advisers reduced its Novo Nordisk (NVO) stake by 74% in Q1 2026, selling an estimated $1.59M and leaving 11,936 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Parallax Volatility Advisers first reported a position in NVO in Q1 2018 and has held it in 17 quarters since. The position peaked at $12.1M in Q3 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Parallax Volatility Advisers held 11,936 shares of Novo Nordisk worth $471K as of Q1 2026.
  • Parallax Volatility Advisers sold 33,490 Novo Nordisk shares in Q1 2026, an estimated $1.59M.
  • Novo Nordisk made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q1 2026, its #1071 holding.
  • Parallax Volatility Advisers first reported a position in Novo Nordisk in Q1 2018 and has held it in 17 quarters since.
  • Parallax Volatility Advisers's Novo Nordisk position peaked at $12.1M in Q3 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.